MDT

96.72

+0.86%↑

146.35

-0.6%↓

VEEV

230.66

-2.38%↓

HQY

84.44

-1.23%↓

PHR.US

16.51

-3.73%↓

MDT

96.72

+0.86%↑

146.35

-0.6%↓

VEEV

230.66

-2.38%↓

HQY

84.44

-1.23%↓

PHR.US

16.51

-3.73%↓

MDT

96.72

+0.86%↑

146.35

-0.6%↓

VEEV

230.66

-2.38%↓

HQY

84.44

-1.23%↓

PHR.US

16.51

-3.73%↓

MDT

96.72

+0.86%↑

146.35

-0.6%↓

VEEV

230.66

-2.38%↓

HQY

84.44

-1.23%↓

PHR.US

16.51

-3.73%↓

MDT

96.72

+0.86%↑

146.35

-0.6%↓

VEEV

230.66

-2.38%↓

HQY

84.44

-1.23%↓

PHR.US

16.51

-3.73%↓

Strona główna・Stock List・Voyager Therapeutics Inc

Voyager Therapeutics Inc

Open

3.9 2.09

Buy Sell

Overview

Share price change

24h

Current

Min

3.84

Max

4.03

Key metrics
By Trading Economics
Income	5.5M -28M
Sales	8.2M 13M
Profit margin	-208.694
Employees	172
EBITDA	8.7M -27M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+225.12% upside

Dividends
By Dow Jones
Next Earnings	10 mar 2026

Market Stats
By TradingEconomics
Market Cap	-28M 227M
Previous open	1.81
Previous close	3.9

Technical Score

By Trading Central

Confidence

Bearish Evidence

3.17 / 3.4644 Support & Resistance

Voyager Therapeutics Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

12 sty 2026, 23:54 UTC

Market Talk

CBA Could Underperform Again in 2026 -- Market Talk

12 sty 2026, 23:48 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

12 sty 2026, 23:48 UTC

Market Talk

Nikkei May Rise on Weaker Yen -- Market Talk

12 sty 2026, 23:43 UTC

Market Talk

Gold Edges Lower on Likely Technical Correction -- Market Talk

12 sty 2026, 23:18 UTC

Acquisitions, Mergers, Takeovers

Paramount Sues Warner Bros., Plans Proxy Fight. The Ellisons Aren't Giving Up. -- Barrons.com

12 sty 2026, 21:56 UTC

Market Talk

Light & Wonder Gets Positive Outcome From Lawsuit -- Market Talk

12 sty 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

12 sty 2026, 21:50 UTC

Market Talk

Health Care Roundup: Market Talk

12 sty 2026, 21:50 UTC

Market Talk

Earnings

Auto & Transport Roundup: Market Talk

12 sty 2026, 21:18 UTC

Market Talk

Global Equities Roundup: Market Talk

12 sty 2026, 21:18 UTC

Market Talk

Pfizer CEO Sees Large Cash Market for Obesity Drugs -- Market Talk

12 sty 2026, 20:54 UTC

Earnings

Gap, Fortinet, and More Stocks That Usually Outperform After Earnings -- Barrons.com

12 sty 2026, 20:48 UTC

Market Talk

Oil Futures Settle Higher in Choppy Trade -- Market Talk

12 sty 2026, 20:33 UTC

Market Talk

U.S. Natural Gas Jumps on Colder Weather Outlook -- Market Talk

12 sty 2026, 20:18 UTC

Acquisitions, Mergers, Takeovers

Credit Agricole Sees Banco BPM Stake Helping 2025 Net by EUR200M >ACA.FR

12 sty 2026, 20:18 UTC

Acquisitions, Mergers, Takeovers

Credit Agricole: European Central Bank Approves Crossing of 20% Threshold in Share Capital of Banco BPM

12 sty 2026, 19:39 UTC

Market Talk

J&J CEO: Trump Pact Allows Company to Focus on Core Operations -- Market Talk

12 sty 2026, 19:36 UTC

Market Talk

Gold and Silver Set New Records on Fed Probe -- Market Talk

12 sty 2026, 19:36 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

12 sty 2026, 19:33 UTC

Market Talk

Venezuela's 'Proven' Oil Reserves Raises Questions -- Market Talk

12 sty 2026, 19:24 UTC

Acquisitions, Mergers, Takeovers

Dynavax: 'Party A' CEO Sent a Non-Binding $15/Shr Proposal on Dec. 23

12 sty 2026, 19:22 UTC

Acquisitions, Mergers, Takeovers

Dynavax Files Tender Offer Recommendation Statement Related to Sanofi Deal, Mentions Talks With 'Party A'

12 sty 2026, 18:21 UTC

Acquisitions, Mergers, Takeovers

Paramount Plans Proxy Fight to Push Hostile Warner Bid -- 2nd Update

12 sty 2026, 18:20 UTC

Acquisitions, Mergers, Takeovers

This French Biotech Stock Surged 1,700% in 2025. Eli Lilly Is Taking an Interest. -- Barrons.com

12 sty 2026, 18:19 UTC

Market Talk

Modest Canadian Economic Impact Seen from Venezuela Changes -- Market Talk

12 sty 2026, 18:16 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Comcast Could Unlock Value With a Spinoff of NBCUniversal Assets, Analysts Say -- Market Talk

12 sty 2026, 18:09 UTC

Market Talk

Global Equities Roundup: Market Talk

12 sty 2026, 18:09 UTC

Market Talk

Baidu's Outlook Bodes Well For Shares -- Market Talk

12 sty 2026, 18:01 UTC

Acquisitions, Mergers, Takeovers

QXO Is Raising Another $1.8 Billion for Its M&A War Chest -- Barrons.com

12 sty 2026, 18:00 UTC

Market Talk

Canada's 'Breakeven' Employment Recalibrating -- Market Talk

Peer Comparison

Price change

Voyager Therapeutics Inc Forecast

Price Target

By TipRanks

225.12% upside

12 Months Forecast

Average 13.2 USD 225.12%

High 25 USD

Low 8 USD

Based on 7 Wall Street analysts offering 12 month price targets forVoyager Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

7 ratings

Buy

Hold

Sell

Based on 7 analysts giving stock ratings to Voyager Therapeutics Inc - Dist in the past 3 months.

Technical Score

By Trading Central

3.17 / 3.4644Support & Resistance

Recent bearish events outweigh bullish events.

All events are bearish.

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Voyager Therapeutics Inc

Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.